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t's a happy picture: President Bush beaming, flanked by smiling members of Congress, as he signs the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005. It was one of the few pieces of health care-related pieces of legislation to reach his desk during the last session.
"For a bill that, in the scheme of things, was small, for it to rise to the level where the President invites the members of Congress who were involved in this effort to the White House and they have a signing ceremony in the Oval Office, with photographs and such; that's pretty amazing," says Licy DoCanto, who was with the American Cancer Society's Government Relations Office at the time.
For reasons I'll explain shortly, I took a personal interest in the recollections of DoCanto and other supporters of patient navigator programs, such as former Harlem Hospital Cancer Chief Harold Freeman, MD. They have pushed for many years to expand the use of these trained lay people, who help guide patients through treatment and bridge the gulf between the worlds of patients and physicians. They used all the standard lobbying techniques to move a bill funding more patient navigator programs.
But they also got an assist from some unusual "testimony:"
In 
'Refusal of Care' Episode
In the episode titled "Refusal of Care," doctors were trying to persuade a reluctant patient to accept treatment for the advanced cancer they had stumbled on while treating her for a bone fracture. The woman blocked out the pleas of white-coated physicians, but opened up to a cancer survivor.
"I brought it to them," says DoCanto. "Here we took a very popular program and we said, 'Even ER has picked up on the importance of patient navigation and if even they have, then you've got to know that there's relevance for this. So it was another way of stimulating the people who were working on it." DoCanto notes that members of Congress are besieged by pleas for action…so anything that can cut through the clutter is useful. "They are real people, too. They watch these programs. I think they do have an impact." DoCanto got the video from Dr. Freeman, who had worked with ER writers to create the storyline.
Dr. Freeman, now a Senior Adviser to the Director of the NCI on cancer disparities and Medical Director of the Ralph Lauren Center for Cancer Care and Prevention in New York City, says the collaboration began with a briefing set up by the Hollywood, Health & Society program at USC Annenberg's Norman Lear Center. He told the ER writers about patients who resisted surgery because they had the mistaken belief that if air touches a tumor, the cancer will spread.
Dr. Freeman, a member of OT's Editorial Board, said he suspects the myth may spring from stories of people who did not appear to be seriously ill until after they were treated.
"The community translates the case into, I believe: 'John walked into the emergency room. He was strong enough to walk in. They operated on him. He seemed to tolerate the surgery okay; he was discharged in 10 days. And then he died.' So the translation is: 'The air touched the cancer and caused the cancer to spread,'" Dr. Freeman said.
The 
Combination Key
As with many other newly developed targeted therapies, treatments targeting the stromal-epithelial connection would have to be used as part of a combination regimen, Dr. Logothetis said. Blocking the bone stroma alone would not be curative, although it could be a strategy to prolong survival. "Therapies blocking the stroma plus cytotoxic therapies is how we envision it," he said.
Early Clinical Research with Thalidomide
He described early clinical research at M. D. Anderson using thalidomide, an agent that is active in disrupting the interaction between a primary prostate cancer tumor and the bone stroma. Thalidomide is not an ideal drug for this purpose because of its adverse effects, he noted, but there are new agents in development that do possess many of the properties of thalidomide without the toxicity.
Dr. Logothetis said researchers saw a disruption of the stromal-epithelial interaction with thalidomide administration, but importantly this was seen prior to any evidence of an effect on the epithelial compartments.
This validated the principle of targeting the host component in metastatic disease as a therapeutic approach.
He mentioned some of the new agents in ongoing experiments that might interfere with this interaction: Atrasentan, a selective endothelin-A receptor antagonist, was the first to enter major trials and is now being tested in combination with chemotherapy. Sunitinib, an inhibitor targeting several receptor tyrosine kinases, is also being studied in combination with chemotherapy, as is the Src oncogene inhibitor dasatinib. And researchers will soon be using insulin-like growth factor-1 blocking pathways in combination with chemotherapy, he said.
'Cutting Edge'
Another speaker at the meeting, Gregory R. Mundy, MD, the John A. Oates Chair in Translational Medicine and Director of the Vanderbilt University Center for Bone Biology, spoke about this osseous-epithelial interaction in an interview at the meeting. "That's just been characterized in the last several years, and it's clearly going to be very important for metastasis and maybe for the dormant state of some tumor cells," Dr. Mundy said. "That's cutting-edge stuff."
He said other speakers had described how cells now being identified in the bone marrow actually prepare the metastatic site of the tumor cells to later settle down and grow. These are also in the bone marrow, he said, but presumably the whole process is directed by the primary tumor cells.
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continued from page 22 had left his poor Chicago neighborhood, gained an education and a medical degree; but he had lost the ability to connect with people who were once his neighbors.
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viability, and motility were not remarkably different between Cetuximab-treated and control male monkeys. It is not known if Cetuximab can impair fertility in humans.
Pregnancy Category C Animal reproduction studies have not been conducted with Cetuximab. However, the EGFR has been implicated in the control of prenatal development and may be essential for normal organogenesis, proliferation, and differentiation in the developing embryo. In addition, human IgG1 is known to cross the placental barrier; therefore Cetuximab has the potential to be transmitted from the mother to the developing fetus. It is not known whether ERBITUX can cause fetal harm when administered to a pregnant woman or whether ERBITUX can affect reproductive capacity. There are no adequate and well-controlled studies of ERBITUX in pregnant women. ERBITUX should only be given to a pregnant woman, or any woman not employing adequate contraception if the potential benefit justifies the potential risk to the fetus. All patients should be counseled regarding the potential risk of ERBITUX treatment to the developing fetus prior to initiation of therapy. If the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the fetus and/or the potential risk for loss of the pregnancy.
Nursing Mothers It is not known whether ERBITUX is secreted in human milk. Because human IgG is secreted in human milk, the potential for absorption and harm to the infant after ingestion exists. Based on the mean halflife of Cetuximab after multiple dosing of 114 hours [range 75-188 hours] (see CLINICAL PHARMA-COLOGY: Human Pharmacokinetics in Full Prescribing Information), women should be advised to discontinue nursing during treatment with ERBITUX and for 60 days following the last dose of ERBITUX.
Pediatric Use The safety and effectiveness of ERBITUX in pediatric patients have not been established.
Geriatric Use Of the 424 patients with head and neck cancer who received ERBITUX with radiation therapy or radiation therapy alone, 110 patients were 65 years of age or older [65 (30%) in the radiation therapy alone arm, 45 (21%) in the radiation and ERBITUX arm]. In a subgroup analysis of patients less than 65 years of age, the hazard ratio of the radiation and ERBITUX arm versus radiation therapy alone arm for duration of locoregional control was 0.68 (95% confidence interval 0.50-0.93), and in patients age 65 years and older the hazard ratio was 0.87 (95% confidence interval 0.56-1.37). For overall survival, the hazard ratio in patients less than 65 years of age was 0.68 (95% confidence interval 0.49-0.94), and in patients age 65 years and older the hazard ratio was 1.15 (95% confidence interval 0.72-1.84). Of the 774 patients who received ERBITUX with irinotecan or ERBITUX monotherapy in four advanced colorectal cancer studies, 253 patients (33%) were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients.
ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does,
WARNING
"And then a patient navigator was brought in who started to get through to her. It was somebody like her from the community, who had cancer that had spread to the bone and was in remission three years out," Dr. Sachs says. "And that clip worked dramatically for Pratt, who is educated and smart, to have to confront some of these beliefs."
Dr. Sachs had latched onto the cancer myths and patient navigator concepts brought to him by a New York City oncologist because of their dramatic potential. It was a bonus that the ER episode then echoed from Los Angeles back to Washington, DC.
'Remarkable Circle'
"So that's a remarkable circle of that story, starting with the kernel of an idea from a briefing about the fact that there are differences in cancer statistics in the inner city and in more suburban areas, talking to the expert, Dr. Harold Freeman, coming up with a compelling dramatic story for Pratt and then, as a side effect, having it result in the passage of congressional legislation that's going to affect millions of people. That's a cool story," Dr. Sachs says.
Licy DoCanto says that of course many people worked on many efforts over several years to win federal funding for patient navigator programs, such as Gilbert H. Friedell, MD, at the University of Kentucky Cancer Center, who could show that the problems weren't restricted to big cities. But the ER episode came along at the right time, and it dovetailed with other media outreach, such as Dr. Freeman's work with the Ralph Lauren Center and Spanish-language radio programs done by Elmer E. Huerta, MD, MPH, of Washington Cancer Institute.
"The media, without a doubt, was critical as an influence," DoCanto says.
Staffers Who Worked on the Legislation Credit the Show with Helping to Raise Awareness
Representative (now Senator) Bob Menendez (D-NJ) sponsored the House bill to fund patient navigator programs. His spokesman, Allyn Brooks-LaSure, says that staffers who worked on the legislation credit the ER clips with helping to raise awareness.
"They didn't see any sort of direct
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however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. The
Immunogenicity
As with all therapeutic proteins, there is potential for immunogenicity. Potential immunogenic responses to Cetuximab were assessed using either a double antigen radiometric assay or an enzyme-linked immunosorbant assay. Due to limitations in assay performance and sampling timing, the incidence of antibody development in patients receiving ERBITUX (Cetuximab
most common adverse events seen in 208 patients receiving ERBITUX in combination with radiation therapy were acneform rash (87%), mucositis (86%), radiation dermatitis (86%), weight loss (84%), xerostomia (72%), dysphagia (65%), asthenia (56%), nausea (49%), constipation (35%), and vomiting (29%). The most common adverse events seen in 103 patients receiving ERBITUX monotherapy were acneform rash (76%), asthenia (45%), pain (28%), fever (27%), and weight loss (27%).
The data in Table 1 movement as a result of it being included in the episode on television; no specific action or follow-up," BrooksLaSure says. "But they believe that it was helpful from a practical perspective, because it provided a tangible example of exactly how the patient navigator program would work-sort of a tool to be able to point people to."
Personal Interest from CNN Work 15 Years Ago
Does a dramatic story have a different sort of persuasive power than standard hearing testimony or a straight factual report, such as a news story? That's where my personal interest in this episode of health care legislative lobbying comes in. You see, I did a series of reports on cancer in poor communities that included Dr. Freeman and showed a patient navigator at work. That series aired on CNN 15 years ago. I'm not aware that the stories produced any movement on related health care policy.
Maybe it was a confluence of factors that led to federal funding for patient navigator programs just months after they were mentioned on ER. But I think that at the very least, the show was a bellwether of popular attitudes. The way that the patient navigator was portrayed indicated that the mood had (continued on page 28)
